The vitamin D3 pathway in human skin and its role for regulation of biological processes

Photochemistry and Photobiology

Volumn 81, Issue 6, 2005, Pages 1246-1251

  Lehmann, Bodo ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLECALCIFEROL; DRUG DERIVATIVE;

CHEMISTRY; HUMAN; KERATINOCYTE; METABOLISM; PHYSIOLOGY; RADIATION EXPOSURE; REVIEW; SIGNAL TRANSDUCTION; SKIN; SUNLIGHT; ULTRAVIOLET RADIATION;

CHOLECALCIFEROL; HUMANS; KERATINOCYTES; SIGNAL TRANSDUCTION; SKIN; SUNLIGHT; ULTRAVIOLET RAYS;

EID: 29844438800     PISSN: 00318655     EISSN: None     Source Type: Journal    
DOI: 10.1562/2005-02-02-IR-430     Document Type: Review

References (55)

1. 3 in human skin and the physiologic consequences. Science 210, 203-205.
2. Prosser, D. E. and G. Jones (2004) Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem. Sci. 29, 664-673.
3. Ohyama, Y. and T. Yamasaki (2005) Eight cytochrome P450S catalyze vitamin D metabolism. Front Biosci. 10, 608-619.
4. Matsumoto, K., Y. Azuma, M. Kiyoki, H. Okumura, K. Hashimoto and K. Yoshikawa (1991) Involvement of endogenously produced 1,25-dihydroxyvitamin D-3 in the growth and differentiation of human keratinocytes. Biochim. Biophys. Acta 1092, 311-318.
5. 3) on vitamin D photosynthesis in patients with psoriasis. J. Am. Acad. Dermatol. 35, 690-695.
6. Bikle, D. D. and E. Gee (1989) Free, and not total 1,25-dihydroxyvitamin D regulates 25-hydroxyvitamin D metabolism by keratinocytes. Endocrinology 124, 649-654.
7. Mendel, C. M. (1989) The free hormone hypothesis: a physiologically based mathematical model. Endocr. Rev. 10, 232-274.
8. Bikle, D. D., B. P. Halloran, E. Gee, E. Ryzen and J. G. Haddad (1986) Free 25-hydroxyvitamin D levels are normal in subjects with liver diseases and reduced total 25-hydroxyvitamin D levels. J. Clin. Invest. 78, 748-752.
9. 3 production by human keratinocytes. J. Clin. Invest. 78, 557-566.
10. 3 in an in vitro human skin equivalent model. J. Invest. Dermatol. 117, 1179-1185.
11. 3-hydroxylases. Steroids 66, 399-408.
12. Segaert, S. and R. Bouillon (2000) Epidermal keratinocytes as source and target cells for vitamin D. In: Vitamin D Endocrine System: Structural, Biological, Genetic and Clinical Aspects. (Edited by A. W. Norman, R. Bouillon and M. Thomasset), pp. 583-590. Proceedings of the Eleventh Workshop on Vitamin D, Nashville, TN 27 May-1 June 2000. Printing and Reprographics University of California, Riverside.
13. 3 (calcitriol) in human skin by microdialysis. Arch. Dermatol. Res. 295, 24-28.
14. 3 potentiates the keratinocyte response to calcium. J. Biol. Chem. 269, 14723-14729.
15. Vantieghem, K., P. Dehaes, R. Bouillon and S. Segaert (2003) Cultured fibroblasts produce non-active vitamin D metabolites that can be activated by cultured keratinocytes. In: Abstracts of the Twelfth Workshop on Vitamin D, p. 27. Maastricht, The Netherlands, 6-10 July 2003.
16. Gniadecki, R. (1996) Stimulation versus inhibition of keratinocyte growth by 1,25-dihydroxyvitamin D3: dependence on cell culture conditions. J. Invest. Dermatol. 106(3), 510-516.
17. Reichrath, J., S. M. Müller, A. Kerber, H. P. Baum and F. A. Bahmer (1997) Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin. J. Am. Acad. Dermatol. 36, 19-28.
18. 3) application in the treatment of psoriasis: an immunohistological evaluation. Acta Derm. Venereol. (Stockh.) 77, 268-272.
19. 3 and its analogs for the treatment of psoriasis. In: Vitamin D: Physiology, Molecular Biologic and Clinical Aspects. (Edited by M. F. Holick), pp. 357-373. The Humana Press Inc., Totowa, NY.
20. 3 as pluripotent immunomodulators. J. Cell. Biochem. 88, 223-226.
21. Boonstra A., F. J. Barrat, C. Crain, V. L. Heath, H. F. Savelkoul and A. O'Garra (2001) 1alpha,25-Dihydroxyvitamin D3 has a direct effect on naïve CD4(+) T cells to enhance the development of Th2 cells. J. Immunol. 167, 4974-4980.
22. Dam, T. N., S. Kang, B. J. Nickoloff and J. J. Voorhees (1999) 1alpha, 25-Dihydroxycholecalciferol and cycloeporin suppress induction and promote resolution of psoriasis in human skin grafts transplanted on to SCID mice. J. Invest. Dermatol. 113, 1082-1089.
23. Ghoreschi K., U. Mrowietz and M. Röcken (2003) A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses. J. Mol. Med. 81, 471-480.
24. Nickoloff, B. J., P. von den Driesch, S. P. Raychaudhuri, W. H. Boehncke, V. B. Morhenn, E. M. Farber, M. F. Holick and J. M. Schröder (2000) Is psoriasis a T-cell disease? Exp. Dermatol. 9, 359-375.
25. Solvoll, K., E. Soyland, B. Sandstad and C. A. Drevon (2000). Dietary habits among patients with atopic dermatitis. Eur. J. Clin. Nutr. 54(2), 93-97.
26. Heine, G., K. Anton, B. M. Henz and M. Worm (2002) 1α,25- Dihydroxyvitamin D3 inhibits anti-CD40 plus IL-4-mediated IgE production in vitro. Eur. J. Immunol. 32(12), 3395-3404.
27. Katayama, I., K. Minatohara, H. Yokozeki and K. Nishioka (1996) Topical vitamin D3 downregulates IgE-mediated murine biphasic cutaneous reactions. Int. Arch. Allergy Immunol. 111(1), 71-76.
28. 3 analog with reduced hypercalcemic activity. J. Invest. Dermatol. 119, 1434-1442.
29. 3 in HL-60 cells. Role in cell differentiation. J. Biol. Chem. 264, 19076-19080.
30. Bielawska, A., C. M. Linardic and Y. A. Hannun (1992) Modulation of cell growth and differentiation by ceramide. FEBS Lett. 307, 211-214.
31. 3 induces sphingomyelin hydrolysis in HaCaT cells via tumor necrosis factor α. J. Biol. Chem. 272, 8997-9001.
32. 3 protects human keratinocytes from apoptosis by the formation of sphingosine-1-phosphate. J. Invest. Dermatol. 117, 1241-1249.
33. 3-induced metallothionein in photoprotection against UV-B injury in mouse skin and cultured rat keratinocytes. J. Dermatol. Sci. 9, 203-208.
34. 3 on ultraviolet light B-induced damage in keratinocyte and its mechanism of action. J. Dermatol. Sci. 18, 11-18.
35. Reichrath, J. (2003) Protecting against adverse effects of sun protection? J. Am. Acad. Dermatol. 49(6), 1204-1206.
36. Holick, M. F. and M. Jenkins (2003) The UV advantage, pp. 94-120. ibooks, distributed by Simon & Schuster, Inc., New York.
37. Holick, M. F. (2002) Vitamin D: The underappreciated D-lightful hormone that is important for skeletal and cellular health. Curr. Opin. Endocrinol. Diabetes 9, 87-98.
38. Hughes, A. M., B. K. Armstrong, C. M. Vajdic, J. Turner, A. E. Grulich, L. Fritsch, S. Milliken, J. Kaldor, G. Benke and A. Kricker (2004) Sun exposure may protect against non-Hodgkin lymphoma: a case-control study. Int. J. Cancer 112, 865-871.
39. Smedby, K. E., H. Hjalgrim, M. Melbye, A. Torrang, K. Rostgaard, L. Munksgaard, J. Adami, M. Hansen, A. Porwit-MacDonald, B. A. Jensen, G. Roos, B. B. Pedersen, C. Sundström, B. Glimelius and H. O. Adami (2005) Ultraviolet radiation exposure and risk of malignant lymphomas. J. Natl. Cancer Inst. 97, 199-209.
40. Berwick, M., B. K. Amstrong, L. Ben-Porat, J. Fine, A. Kricker, C. Eberle and R. Barnhill (2005) Sun exposure and mortality from melanoma. J. Natl. Cancer Inst. 97, 195-199.
41. Egan, K. M., J. A. Sosman and W. J. Blot (2005) Sunlight and reduced risk of cancer: is the real story vitamin D? J. Natl. Cancer Inst. 97, 161-163.
42. Bikle, D. D. (2004) Vitamin D and skin cancer. J. Nutr. 134; 3472S-3478S.
43. 3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D synthesis in human skin. J. Clin. Endocrinol. Metab. 67, 373-378.
44. Quesada, J. M., W. Coopmans, B. Ruiz, P. Aljam, I. Jans and R. Bouillon (1992) Influence of vitamin D on parathyroid function in the elderly. J. Clin. Endocrinol. Metab. 75, 494-501.
45. Matsuoka, L. Y., J. Wortsman, J. G. Haddad, P. Kolm and B. W. Hollis (1991) Racial pigmentation and the cutaneous synthesis of vitamin D. Arch. Dermatol. 127, 536-538.
46. Lips, P. (2001) Vitamin D deficiency and secondary hyperparathyreodism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr. Rev. 22, 477-501.
47. Malabanan, A., I. Veronikis and M. F. Holick (1998) Redefining vitamin D insufficiency. Lancet 351, 805-806.
48. Chapuy, M. C., P. Preziosi, M. Maamer, S. Arnaud, P. Galan, S. Hercberg and P. J. Meunier (1997) Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos. Int. 7, 439-443.
49. Vieth, R. (1999) Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am. J. Clin. Nutr. 69, 842-856.
50. Hollis, B. W. (2005) Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J. Nutr. 13, 317-322.
51. Calvo, M. S., S. J. Whiting and N. Barton (2005) Vitamin D intake: a global perspective of current status. J. Nutr. 135, 310-316.
52. DeLuca, H. F. (2004) Overview of general physiologic features and functions of vitamin D. Am. J. Clin. Nutr. 80(Suppl.), 1689S-1696S.
53. 2. Am. J. Clin. Nutr. 68, 854-858.
54. Koutkia, P., T. C. Chen and M. F. Holick (2001) Vitamin D intoxication with an over-the counter supplement. New Engl. J. Med. 345, 66-67.
55. Heikkinen, A. M., M. T. Tupporainen, L. Niskanen M. Komulainen, I. Pentillä and S. Saarikoski (1997) Long-term vitamin D supplementation may have adverse effects on serum lipids during postmenopausal hormone replacement therapy. Eur. J. Endocrinology 137, 495-502.